Published in Drug Saf on January 01, 2002
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study. BMC Geriatr (2013) 0.88
Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol (2004) 0.86
To self-cite or not to self-cite. CMAJ (2004) 0.75
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med (2007) 4.68
Trends in hip fracture rates in Canada. JAMA (2009) 2.95
Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ (2009) 2.64
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int (2004) 2.09
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
A systematic review and meta-analysis of studies using the STRATIFY tool for prediction of falls in hospital patients: how well does it work? Age Ageing (2008) 1.94
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy. J Rheumatol (2009) 1.70
Diagnosis and management of vertebral fractures in elderly adults. Am J Med (2002) 1.68
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev (2013) 1.63
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Effect of low-intensity pulsed ultrasound on the cartilage repair in people with mild to moderate knee osteoarthritis: a double-blinded, randomized, placebo-controlled pilot study. Arch Phys Med Rehabil (2012) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol (2008) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns (2002) 1.53
References to anesthesia, pain, and analgesia in the Hippocratic Collection. Anesth Analg (2009) 1.48
The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord (2002) 1.47
Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause (2013) 1.47
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev (2002) 1.44
Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging (2007) 1.44
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. J Obstet Gynaecol Can (2004) 1.38
Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract (2006) 1.36
Emergency Department and Walk-in Clinic Use in Models of Primary Care Practice with Different After-Hours Accessibility in Ontario. Healthc Policy (2008) 1.36
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int (2005) 1.31
Management of osteoporosis in men: an update and case example. CMAJ (2007) 1.29
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res (2007) 1.28
Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord (2005) 1.27
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Bone strength: the whole is greater than the sum of its parts. Semin Arthritis Rheum (2006) 1.18
Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res (2012) 1.18
Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther (2004) 1.17
Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res (2009) 1.17
Do patients perceive a link between a fragility fracture and osteoporosis? BMC Musculoskelet Disord (2008) 1.16
Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res (2009) 1.15
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. Curr Osteoporos Rep (2013) 1.11
Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol (2006) 1.09
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int (2003) 1.09
The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. Qual Life Res (2006) 1.08
Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician (2008) 1.08
Pain management decision making among long-term care physicians and nurses. West J Nurs Res (2007) 1.07
Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2004) 1.06
Fracture risk in living kidney donors: a matched cohort study. Am J Kidney Dis (2012) 1.06
An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW). Ann Rheum Dis (2012) 1.06
Retracted Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. Am J Kidney Dis (2009) 1.05
Prediction of falls using a risk assessment tool in the acute care setting. BMC Med (2004) 1.05
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med (2002) 1.05
Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc (2013) 1.05
Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr (2008) 1.03
Bridging the osteoporosis quality chasm. J Bone Miner Res (2009) 1.03
The detection and management of vaginal atrophy. J Obstet Gynaecol Can (2004) 1.01
Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr (2009) 1.01
Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res (2009) 1.00
Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone (2008) 1.00
Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis. Ther Clin Risk Manag (2011) 1.00
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord (2011) 0.99
Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab (2013) 0.99
Minimum joint space width and tibial cartilage morphology in the knees of healthy individuals: a cross-sectional study. BMC Musculoskelet Disord (2008) 0.99
An interdisciplinary knowledge translation intervention in long-term care: study protocol for the vitamin D and osteoporosis study (ViDOS) pilot cluster randomized controlled trial. Implement Sci (2012) 0.98
Determinants of health-related quality of life in women with vertebral fractures. Osteoporos Int (2005) 0.97
Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. Nat Clin Pract Rheumatol (2008) 0.97
Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin Exp Res (2008) 0.97
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord (2010) 0.96
A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents. PLoS One (2010) 0.95
Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort. Bone (2012) 0.95
The burden of osteoporotic fractures beyond acute care: the Canadian Multicentre Osteoporosis Study (CaMos). Age Ageing (2011) 0.94
Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res (2012) 0.94
Efficacy of vitamin D supplementation in depression in adults: a systematic review. J Clin Endocrinol Metab (2013) 0.93
Association of larger holes in the trabecular bone at the distal radius in postmenopausal women with type 2 diabetes mellitus compared to controls. Arthritis Care Res (Hoboken) (2012) 0.93
Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord (2002) 0.92